Acute graft rejection

1. Everolimus has no effect on acute graft rejection in humans (15% vs 15%).

   “similar for the full study period (23 [15%] vs 22 [15%])”

   Human trialfor the full study period in kidney transplant recipientskidney12 monthsn = 300

   Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

   Lancet (London, England)·19 Feb 2011

2. Everolimus increases acute graft rejection in humans (10% vs 3% (p = 0.036)).

   “Rates of biopsy-proven acute rejection were higher in the everolimus group than in the ciclosporin group after randomisation (15 [10%] of 154 vs five [3%] of 146; p = 0·036)”

   Human trialpost-randomisation in recipients of de-novo kidney transplantskidney12 monthsn = 300

   Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

   Lancet (London, England)·19 Feb 2011

More on Everolimus